25.96
-0.08 (-0.31%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Tyra Biosciences, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 1.5 |
| 内部交易活动 | -3.0 |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.00 |
|
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company’s in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 3.69% |
| 机构持股比例 | 108.46% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Alta Partners Management Company, L.P. | 30 Sep 2025 | 4,080,296 |
| Canaan Partners Xi Llc | 30 Sep 2025 | 3,608,109 |
| 5Am Venture Management, Llc | 30 Sep 2025 | 939,298 |
| 52周波幅 | ||
| 中 | 37.00 (42.53%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Wedbush | 16 Dec 2025 | 37.00 (42.53%) | 购买 | 22.97 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| MORE ROBERT J | - | 25.51 | -10,000 | -255,100 |
| 累积净数量 | -10,000 | |||
| 累积净值 ($) | -255,100 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 25.51 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| MORE ROBERT J | 董事 | 19 Dec 2025 | 自动卖出 (-) | 10,000 | 25.51 | 255,100 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合